PDF(Pubmed)
Abstract：
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8:CD4 ratio, ex vivo culture time, expression of exhaustion markers, costimulatory signals, antitumor reactivity, and scope of target tumor-associated antigens), and other treatment-related factors (such as lymphodepleting chemotherapy and postinfusion administration of interleukin-2).
摘要：
肿瘤浸润淋巴细胞（TIL）的过继性细胞疗法在转移性黑色素瘤患者中表现出持久的临床反应，最近关于TIL治疗的第一个III期试验的阳性结果证实了这一点。作为一种苛刻且后勤复杂的治疗方法，需要广泛的临床前和临床努力，以通过识别反应的预测生物标志物来优化患者选择。这篇综述旨在全面总结当前关于肿瘤相关因素（如突变负担，新抗原负荷，免疫浸润，致癌驱动基因的状态，和表观遗传修饰)，患者特征(包括疾病负担和位置，基线细胞因子和乳酸脱氢酶血清水平，人类白细胞抗原单倍型，或事先接触过免疫检查点抑制剂和其他抗癌疗法)，转移的T细胞的表型特征(主要是总细胞计数，CD8:CD4比值,离体培养时间，耗尽标记的表达，共刺激信号,抗肿瘤反应性，和靶肿瘤相关抗原的范围)，和其他治疗相关因素（如淋巴消耗化疗和输注白细胞介素-2后）。
